Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause
INTRODUCTION: Estrogens used in women's healthcare have been associated with increased risks of venous thromboembolism (VTE) and breast cancer. Estetrol (E4), an estrogen produced by the human fetal liver, has recently been approved for the first time as a new estrogenic component of a novel combined oral contraceptive (E4/drospirenone [DRSP]) for over a decade. In phase 3 studies, E4/DRSP showed good contraceptive efficacy, a predictable bleeding pattern, and a favorable safety and tolerability profile.
AREAS COVERED: This narrative review discusses E4's pharmacological characteristics, mode of action, and the results of preclinical and clinical studies for contraception, as well as for menopause and oncology.
EXPERT OPINION: Extensive studies have elucidated the properties of E4 that underlie its favorable safety profile. While classical estrogens (such as estradiol) exert their actions via both activation of nuclear and membrane estrogen receptor α (ERα), E4 presents a specific profile of ERα activation: E4 binds and activates nuclear ERα but does not induce the activation of membrane ERα signaling pathways in specific tissues. E4 has a small effect on normal breast tissue proliferation and minimally affects hepatic parameters. This distinct profile of ERα activation, uncoupling nuclear and membrane activation, is unique.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Expert review of clinical pharmacology - 15(2022), 2 vom: 09. Feb., Seite 121-137 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gérard, Céline [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Combined oral contraception |
|---|
| Anmerkungen: |
Date Completed 31.03.2022 Date Revised 01.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17512433.2022.2054413 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338374515 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338374515 | ||
| 003 | DE-627 | ||
| 005 | 20231226000528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17512433.2022.2054413 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1127.xml |
| 035 | |a (DE-627)NLM338374515 | ||
| 035 | |a (NLM)35306927 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gérard, Céline |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2022 | ||
| 500 | |a Date Revised 01.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Estrogens used in women's healthcare have been associated with increased risks of venous thromboembolism (VTE) and breast cancer. Estetrol (E4), an estrogen produced by the human fetal liver, has recently been approved for the first time as a new estrogenic component of a novel combined oral contraceptive (E4/drospirenone [DRSP]) for over a decade. In phase 3 studies, E4/DRSP showed good contraceptive efficacy, a predictable bleeding pattern, and a favorable safety and tolerability profile | ||
| 520 | |a AREAS COVERED: This narrative review discusses E4's pharmacological characteristics, mode of action, and the results of preclinical and clinical studies for contraception, as well as for menopause and oncology | ||
| 520 | |a EXPERT OPINION: Extensive studies have elucidated the properties of E4 that underlie its favorable safety profile. While classical estrogens (such as estradiol) exert their actions via both activation of nuclear and membrane estrogen receptor α (ERα), E4 presents a specific profile of ERα activation: E4 binds and activates nuclear ERα but does not induce the activation of membrane ERα signaling pathways in specific tissues. E4 has a small effect on normal breast tissue proliferation and minimally affects hepatic parameters. This distinct profile of ERα activation, uncoupling nuclear and membrane activation, is unique | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Combined oral contraception | |
| 650 | 4 | |a E4 | |
| 650 | 4 | |a contraception | |
| 650 | 4 | |a estetrol | |
| 650 | 4 | |a estrogen | |
| 650 | 4 | |a estrogen receptor | |
| 650 | 4 | |a hemostasis | |
| 650 | 4 | |a menopause | |
| 650 | 4 | |a venous thrombosis | |
| 650 | 7 | |a Contraceptives, Oral, Combined |2 NLM | |
| 650 | 7 | |a Estrogens |2 NLM | |
| 650 | 7 | |a Estetrol |2 NLM | |
| 650 | 7 | |a ENB39R14VF |2 NLM | |
| 700 | 1 | |a Arnal, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Jost, Maud |e verfasserin |4 aut | |
| 700 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Lenfant, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Fontaine, Coralie |e verfasserin |4 aut | |
| 700 | 1 | |a Houtman, René |e verfasserin |4 aut | |
| 700 | 1 | |a Archer, David F |e verfasserin |4 aut | |
| 700 | 1 | |a Reid, Robert L |e verfasserin |4 aut | |
| 700 | 1 | |a Lobo, Rogerio A |e verfasserin |4 aut | |
| 700 | 1 | |a Gaspard, Ulysse |e verfasserin |4 aut | |
| 700 | 1 | |a Coelingh Bennink, Herjan J T |e verfasserin |4 aut | |
| 700 | 1 | |a Creinin, Mitchell D |e verfasserin |4 aut | |
| 700 | 1 | |a Foidart, Jean-Michel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of clinical pharmacology |d 2008 |g 15(2022), 2 vom: 09. Feb., Seite 121-137 |w (DE-627)NLM192063413 |x 1751-2441 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2022 |g number:2 |g day:09 |g month:02 |g pages:121-137 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17512433.2022.2054413 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2022 |e 2 |b 09 |c 02 |h 121-137 | ||